Drugs / SOR007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03004339 | Aug 2016 → Feb 2017 | psoriasis | DFB Soria, LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03143491 | Oct 2017 → Dec 2018 | cervical intraepithelial neoplasia grade 2/3 | DFB Soria, LLC | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOR007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004339 ↗ |
| Known as | Paclitaxel | “Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment” NCT03143491 ↗ |
| Route | Topical | “Topical application once daily during a 12-day treatment period (10 treatments)” NCT03004339 ↗ |